Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

(RTTNews) - Bristol Myers Squibb (BMY) today announced that the FDA has expanded Breyanzi's approval to include treatment of relapsed or refractory (R/R) marginal zone lymphoma in adult patients who ...

Hematologists and rheumatologists may be able to adopt a more aggressive approach for managing low-grade marginal lymphoma in Sjögren disease, particularly mucosa-associated lymphoid tissue (MALT) ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). Approval was supported by findings from the ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...